RU-486 Review Focus On "Intended Use" Is Appropriate - Henney
• By The Pink Sheet
FDA approval of the abortifacient mifepristone (RU-486) is appropriate provided that the drug is safe and effective for its intended use by pregnant women for termination of pregnancy, FDA Commissioner nominee Jane Henney, MD, told the Senate Labor & Human Resources Committee Aug. 24.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.
A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.
Clarity on what transferable exclusivity vouchers may look like for new antimicrobial drugs could be nearing. Denmark’s new presidency of the Council of the EU has prioritized concluding its negotiations with European Parliament over the legislative overhaul of the EU’s pharmaceutical legislation.